Marketing-authorisation holder · France
Alexion Europe Sas
28 medicines in 4 countries, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · France
28 medicines in 4 countries, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 28
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| Kanuma | Sebelipase alfa | EU (EMA) | Authorised | 2015 |
| KANUMAConcentrato per soluzione per infusione | Sebelipase alfa | Italy | Authorised | |
| Kanuma 2 mg/ml, concentraat voor oplossing voor infusieConcentraat voor oplossing voor infusie | Sebelipase alfa | Netherlands | Authorised | 2015 |
| KANUMA 2 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION20 mg · Concentrado para solución para perfusión | Sebelipase alfa | Spain | Marketed | 2016 |
| Soliris | Eculizumab | EU (EMA) | Authorised | 2007 |
| SOLIRISConcentrato per soluzione per infusione | Eculizumab | Italy | Authorised | |
| SOLIRIS 300 mg CONCENTRADO PARA SOLUCION PARA PERFUSION300 mg · Concentrado para solución para perfusión | Eculizumab | Spain | Marketed | 2007 |
| Soliris, concentraat voor oplossing voor infusie 10 mg/ml (300 mg/30 ml)Concentraat voor oplossing voor infusie | Eculizumab | Netherlands | Authorised | 2007 |
| Strensiq | Asfotase alfa | EU (EMA) | Authorised | 2015 |
| STRENSIQSoluzione iniettabile | Asfotase alfa | Italy | Authorised | |
| Strensiq 100 mg/ml, oplossing voor injectieOplossing voor injectie | Asfotase alfa | Netherlands | Authorised | 2015 |
| STRENSIQ 100 MG/ML SOLUCION INYECTABLE80 mg · Solución inyectable | Asfotase alfa | Spain | Authorised | 2015 |
| Strensiq 40 mg/ml, oplossing voor injectieOplossing voor injectie | Asfotase alfa | Netherlands | Authorised | 2015 |
| STRENSIQ 40 MG/ML SOLUCION INYECTABLE18 mg · Solución inyectable | Asfotase alfa | Spain | Authorised | 2015 |
| STRENSIQ 40 MG/ML SOLUCION INYECTABLE40 mg · Solución inyectable | Asfotase alfa | Spain | Authorised | 2015 |
| STRENSIQ 40 MG/ML SOLUCION INYECTABLE28 mg · Solución inyectable | Asfotase alfa | Spain | Authorised | 2015 |
| ULTOMIRISConcentrato per soluzione per infusione | Ravulizumab | Italy | Authorised | |
| Ultomiris | Ravulizumab | EU (EMA) | Authorised | 2019 |
| Ultomiris 1100 mg/11 ml concentraat voor oplossing voor infusieConcentraat voor oplossing voor infusie | Ravulizumab | Netherlands | Authorised | 2020 |
| ULTOMIRIS 1100 mg/11 ml CONCENTRADO PARA SOLUCION PARA PERFUSION1100 mg · Concentrado para solución para perfusión | Ravulizumab | Spain | Marketed | 2021 |
| Ultomiris 300 mg/3 ml concentraat voor oplossing voor infusieConcentraat voor oplossing voor infusie | Ravulizumab | Netherlands | Authorised | 2019 |
| ULTOMIRIS 300 mg/3 ml CONCENTRADO PARA SOLUCION PARA PERFUSION300 mg · Concentrado para solución para perfusión | Ravulizumab | Spain | Marketed | 2021 |
| VOYDEYACompressa rivestita con film | Danicopan | Italy | Authorised | |
| Voydeya | Danicopan | EU (EMA) | Authorised | 2024 |
| VOYDEYA 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULA100 mg · Comprimido recubierto con película | Danicopan | Spain | Marketed | 2024 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 10 | 10 | 0 | CompaniesAll medicines |
| Netherlands | 8 | 8 | 0 | CompaniesAll medicines |
| European Union (EMA) | 5 | 5 | 0 | CompaniesAll medicines |
| Italy | 5 | 5 | 0 | CompaniesAll medicines |
Also in the registers of France, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.